Monoclonal Antibody Therapy for Treatment-Resistant
Name of the Trial
Why Is This Trial Important?
Siplizumab is a monoclonal antibody that binds to a protein called CD2, which is found abundantly on certain types of lymphocytes including T cells and Natural Killer (NK) cells. Initially developed to treat psoriasis, siplizumab has been shown in clinical studies to trigger T-cell death. This phase I dose-escalation study is investigating safety and tolerability, and will determine the maximum dose of siplizumab that can be given to patients with CD2-positive lymphoproliferative disease.
"Preclinical studies of siplizumab at NCI produced very promising results, with a short course of treatment yielding a 50 percent cure rate in mice with T-cell non-Hodgkin's lymphoma," said Dr. Janik. "Longer courses of treatment led to the treated mice living out their natural life spans.
"Early results from this trial have produced promising responses in some patients, and we hope to follow this research with additional studies combining siplizumab and chemotherapy," Dr. Janik added.
Who Can Join This Trial?
Where Is This Trial Taking Place?
An archive of "Featured Clinical Trial" columns is available at